Translational Science Update of Precision Oncology Methods in Lung Cancer

Presented by: Joel W Neal, MD. PhD

Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH.

 

Dr. Joel Neal
Associate Professor of Medicine at Stanford Cancer Institute

Dr. Joel Neal, Associate Professor of Medicine at Stanford Cancer Institute, provides an update of precision oncology methods in lung cancer focused on circulating tumor DNA (ctDNA). Traditionally, lung cancer treatment was viewed as a ‘one-size-fits-all’ approach. However, it is becoming evident that non-small cell lung cancer (NSCLC) is a molecularly complex amalgam of diseases resulting in vastly different outcomes [1]. As a result, treatment paradigms have shifted towards increasingly personalized approaches, giving rise to ctDNA as a tool for making informed treatment decisions.

 

Plasma-derived ctDNA is the most extensively studied analyte to provide sampling of the molecular content within tumor cells [2]. As such, the assessment of oncogenic driver alterations by ctDNA has become an accepted companion diagnostic for advanced NSCLC. During this session, Dr. Neal provides a growing list of ctDNA applications in the clinical management of NSCLC such as non-invasive diagnosis, monitoring, and detection of recurrence in advanced NSCLC [3-5].

 

Moreover, Dr. Neal highlights that the detection of minimal residual disease (MRD) by ctDNA for patients with NSCLC after curative-intent treatment may serve as a prognostic and potentially predictive biomarker for recurrence and response to therapy [6]. Importantly, Dr. Neal shares some preliminary insights about the Adjuvant ctDNA-Adapted Personalized Treatment in Early-Stage NSCLC (ADAPT-E) trial. The session concludes by emphasizing that future opportunities include improvement of ctDNA sensitivity and looking at other molecules altered by tumors (ctRNA, proteins, metabolites).

 

  1. Gandara et al. JCO 2013.
  2. Crowley et al. Nat Rev Clin Onc 2013.
  3. Oxnard et al. JCO 2016
  4. Zill et al. ASCO 2016
  5. Husain et al. JCO PO 2022.
  6. Chaudhuri et al. Cancer Discovery 2017.

 

 

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

6 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

6 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago